mMRC Dyspnoea Scale
The modified Medical Research Council dyspnoea scale grades functional breathlessness on a 0–4 scale. It is used alongside exacerbation history in the GOLD COPD assessment framework to guide treatment escalation.
inputs
✓ when to use
Use in all patients with COPD as part of GOLD symptom assessment. mMRC ≥2 places the patient in the 'more symptoms' category, which influences inhaler therapy decisions. Also useful for monitoring dyspnoea longitudinally and in pre-pulmonary rehabilitation assessment. Can be used in non-COPD dyspnoea assessment as a simple functional grading tool.
✗ when not to use
The mMRC only measures exertional dyspnoea. It does not capture the broader impact of COPD symptoms (cough, sputum, fatigue, sleep) — the CAT score provides a more comprehensive symptom assessment. Not suitable for assessing acute breathlessness (it reflects chronic/usual functional limitation). Not validated in children.
clinical pearls
- In GOLD 2025, COPD patients are classified into groups A, B, and E based on symptoms (mMRC or CAT) and exacerbation history. mMRC ≥2 = 'more symptoms'. This directly influences whether dual bronchodilation or ICS-containing therapy is initiated.
- The CAT score (COPD Assessment Test) captures more dimensions of COPD impact than mMRC and is generally preferred for comprehensive assessment. However, mMRC is quicker (single question) and sufficient for GOLD group assignment.
- mMRC is patient-reported and subjective. Physical deconditioning, anxiety, obesity, and cardiac disease can all contribute to dyspnoea independent of airflow limitation. Consider the clinical context.
- The threshold of mMRC ≥2 represents meaningful functional limitation — the patient cannot keep pace with age-matched peers. This is a practical, patient-centred definition of 'symptomatic'.
- Monitor mMRC longitudinally. A worsening grade should prompt reassessment of inhaler technique, adherence, exacerbation frequency, and comorbidities — not just a step-up in pharmacotherapy.